Simec

Simcere Pharmaceutical Group is a leading Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of branded generic and innovative pharmaceuticals. The company's portfolio covers oncology, central nervous system disorders, autoimmune conditions, cardiovascular disease, infectious diseases such as COVID‑19 and influenza. It has launched China's first domestically produced 3CL-targeting anti-COVID‑19 drug ("XIANNUOXI") and recently secured exclusive rights to commercialize ADC189 for influenza. Simcere maintains strategic partnerships with global pharma companies like Merck & Co. and Bristol Myers Squibb to co-develop novel therapeutics.